Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors

Biliary tract cancers (BTCs) are rare neoplasms that are mostly reported in first-world countries, with an incidence in Europe of approximately 1 per 100,000 inhabitants. BTCs are categorized as intrahepatic (iCCA), perihilar (pCCA), or distal cholangiocarcinomas (dCCA), or gallbladder carcinomas. Gemcitabine-platinum doublet chemotherapy is the standard-of-care in the first-line for advanced BTCs, giving an 8-month median progression-free-survival (PFS), with median overall survival ranging from 6 to 12 months [1].